🏛️ Verified NIH Record • Updated 2026-04-15
A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis (NCT06906900)
🟢 Recruiting Phase1 ⚙️ Medical Device Protocol Sponsor: M.D. Anderson Cancer Center
🩺 Plain-English Summary (8th-Grade Level)
This clinical research study is to learn about the safety of the NovoTTF-200M and Novo TTF-200A Systems, when used either alone or in combination with standard therapy, in patients with tumors that did not respond to treatment.
Who can join: Review the eligibility criteria below.
Location: The University of Texas M. D. Anderson Cancer Center — Houston, Texas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- The University of Texas M. D. Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (713) 563-8710
Email: cetatsui@mdanderson.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Spinal Metastasis
- Proton SBRT for Spinal Metastasis — Baltimore, Maryland
Explore by condition: All Spinal Metastasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.